Related Experiment Video
Updated: Jul 5, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer
Robert J Amato1, Taqi Mohammad
1The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050 Houston, TX 77030, USA. ramato@tmh.tmc.edu
Abstract:
Thirty patients with progressive metastatic renal cell carcinoma were treated. Eleven patients received 2 or more prior systemic therapies; 2 had a complete response, 7 had a partial response, and 11 had stable disease. The complete responders are off therapy and remain without disease recurrence. The median duration of response was 3.8 months (range 1 - 48+ months). Therapy was well tolerated; predominant toxicities were fatigue, paraesthesias and hand/foot syndrome. The data suggest that the combination of interferon-alpha, thalidomide and capecitabine has anti-tumor activity in previously treated patients with progressive metastatic renal cell carcinoma. A prospective investigation of this combination warranted.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...